Edifice Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.38 Cr
as on 16-11-2024
- Revenue 106.64%
(FY 2023)
- Profit 20.18%
(FY 2023)
- Ebitda 47.14%
(FY 2023)
- Net Worth 61.66%
(FY 2023)
- Total Assets 45.11%
(FY 2023)
About Edifice Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.38 Cr.
Awadhesh Kumar and Vikas serve as directors at the Company.
- CIN/LLPIN
U52609HR2019PTC078658
- Company No.
078658
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Feb 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Edifice Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Awadhesh Kumar  | Additional Director | 16-Jan-2024 | Current |
| Vikas | Director | 20-Feb-2019 | Current |
Financial Performance of Edifice Life Sciences.
Edifice Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 106.64% increase. The company also saw a substantial improvement in profitability, with a 20.18% increase in profit. The company's net worth Soared by an impressive increase of 61.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Edifice Life Sciences?
In 2023, Edifice Life Sciences had a promoter holding of 66.67% and a public holding of 33.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
D'latitude Pharmacy Private LimitedActive 2 years 7 monthsAwadhesh Kumar and Vikas are mutual person
- Prisma Vision Venture Partners Private LimitedActive 3 years 11 months
Awadhesh Kumar and Vikas are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Feb 2024 | ₹3.50 M | Open |
Axis Bank Limited Creation Date: 27 Jun 2023 | ₹8.00 M | Open |
Hdfc Bank Limited Creation Date: 09 Dec 2022 | ₹0.60 M | Open |
How Many Employees Work at Edifice Life Sciences?
Unlock and access historical data on people associated with Edifice Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Edifice Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Edifice Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
